source
- City Therapeutics raises $200M in IPO to fund thromboembolic disease pipelineCity Therapeutics, an RNA interference biotech focused on thromboembolic diseases, completed an initial public offering that raised $200 million. The company sold about 11 million shares at $18 ea…
- HHS moves to let compounding pharmacies make select peptides as China tightens biotech exports but permits foreign licensingThe HHS announced a policy that would allow compounding pharmacies to produce certain peptide drugs, expanding access and potentially lowering costs. The move is part of the Trump administration's…